A

n international tribunal sided against Eli Lilly in a closely watched claim that the drug maker brought against the Canadian government over its right to set patent laws.

The dispute centered on different Canadian court rulings several years ago that invalidated patents on two Lilly drugs. Those decisions prompted the arrival of cheaper generics on the Canadian market, which Lilly claims led to “significant” sales and job losses in Canada.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.